^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1d
    SLC28A3 expression and fludarabine-emergent autoimmune hemolytic anemia in chronic lymphocytic leukemia: A new player in an old equation. (PubMed, Biomol Biomed)
    This retrospective study investigated the relationship between baseline SLC28A3 expression levels, quantified via reverse-transcriptase polymerase chain reaction (qRT-PCR), and the incidence of AIHA in a cohort of CLL patients receiving fludarabine and cyclophosphamide (FC) therapy. These findings suggest that diminished baseline SLC28A3 expression may correlate with an elevated risk of fludarabine-emergent AIHA in CLL patients. Further validation through larger, prospective cohorts is essential to confirm the predictive utility of SLC28A3 expression for optimizing fludarabine-based therapeutic strategies.
    Journal
    |
    SLC28A3 (Solute Carrier Family 28 Member 3)
    |
    cyclophosphamide • fludarabine IV
    1d
    SILENCE: Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea (clinicaltrials.gov)
    P=N/A, N=338, Recruiting, University Hospital, Tours | Trial completion date: May 2024 --> Sep 2028 | Trial primary completion date: Feb 2024 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide
    1d
    19-C-0116: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=132, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2030 --> Mar 2031 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    1d
    KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome (clinicaltrials.gov)
    P2, N=20, Recruiting, Shanghai Changzheng Hospital
    New P2 trial
    |
    cyclophosphamide • carfilzomib
    1d
    The CARDIOPROTECT Trial (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Beth Israel Deaconess Medical Center
    New P2 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • Truxima (rituximab-abbs) • Myocet (non-pegylated liposomal doxorubicin) • Polivy (polatuzumab vedotin-piiq) • dexrazoxane
    1d
    Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov)
    P1, N=20, Recruiting, The First Affiliated Hospital of Soochow University | Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2026 --> Nov 2025
    Enrollment open • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    cyclophosphamide • Nailike (olverembatinib) • fludarabine IV • ThisCART19A
    1d
    Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy (clinicaltrials.gov)
    P1, N=0, Withdrawn, Medical College of Wisconsin | N=20 --> 0 | Initiation date: Mar 2026 --> Jun 2026 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial initiation date • Trial withdrawal
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Bria-IMT (SV-BR-1-GM) • ViraferonPeg (peginterferon-α-2b)
    1d
    Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • melphalan • fludarabine IV
    2d
    CRIMSON-NE: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=27 --> 45 | Trial completion date: May 2040 --> Mar 2041
    Enrollment closed • Enrollment change • Trial completion date
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide
    2d
    AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Mabtas (rituximab biosimilar)
    2d
    ARST1321: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov)
    P2/3, N=140, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • daunorubicin
    2d
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831